<html><head><meta http-equiv='Content-Type' content='text/html; charset=iso-8859-1' /><meta name='copyright' content='&copy; Martin Pule 2008-2014' /><meta name='robots' content='all' /><meta name='description' lang='en-UK' content='EU Framework 7 consortium' /><meta name='keywords' lang='en-UK' content='FP7' /><meta name='keywords' lang='en-UK' content='Chimeric Antigen Receptors' /><meta name='keywords' lang='en-UK' content='Immunotherapy' /><meta name='keywords' lang='en-UK' content='TALENs' /><meta name='keywords' lang='en-UK' content='Cancer Immunotherapy' /><title>welcome to ATECT-FP7</title><style>@import url(./css/pMol.css);</style><style type='text/css'> pre {display: inline;} </style><link rel='icon' type='image/png' href='../images/ATECT_icon.png' /></head><div id='image'><table cellpadding=0 cellspacing=0 border = 0 width=100% align=center><tr><td></td><td><h0><b><i>EU FP7 ATECT</i></b></h0></td></tr><tr><td><table padding='0' border='0'><tr><td>&nbsp</td></tr></table></td><td colspan=2><table padding='0' border='0'><tr><td bgcolor='#e0e0e0' id='mydivide'><a href='index.php'><font id='bbb'>[home]</font></a><a href='about.php'><font id='bbb'>[about]</font></a><a href='partners.php'><font id='bbb'>[partners]</font></a><a href='project.php'><font id='bbb'>[project]</font></a><a href='contact.php'><font id='bbb'>[contact]</font></a><a href='news.php'><font id='bbb'>[news]</font></a><a href='login.php'><font id='bbb'>[login]</font></a></td></tr></table></td></tr><tr><td valign=top><br><a href='http://cordis.europa.eu/fp7/home_en.html'><img width=128 src='./images/logo_7th_framework_programme_12.jpg'></img></a><br></td><td width=100%><br>
<H2>Welcome to the ATECT Research Consortium</H2>
<br>
ATECT stands for "<b><u>A</u></b>dvanced <b><u>T</u></b>-cell <b><u>E</u></b>ngineering for <b><u>C</u></b>ancer <b><u>T</u></b>herapy".<br><br>
We are an EU framework 7 funded consortium whose aims are to apply advanced genetic engineering methodologies to Cancer Therapy.
<br><br>
ATECT is formed of 3 university partners and 2 small/medium sized enterprise partners; ATECT launched on December 2013 and will run for 5 years. Read more about our partners <a href="./partners.php">[our partners]</a>.
<br><br>
We will use a combination of technologies including Chimeric Antigen receptors, lentiviral vectors and genome editing tools to generate highly advanced therapeutic cellular products.
<br><br>
<img src='./images/ATECT_overview.png' width=420><br><br>
Read more <a href="./about.php">[about our technology]</a>.
<br><br>
</td><td width=84px>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp</td></tr></table><hr><table border=0 cellpadding=0 align=center><tr><td align=right><img src='./images/ATECT_EU_flag_small.png' width=48>&nbsp</td><td>The research is funded from the European Community's Seventh Framework Programme<br>2007-2013 FP7-HEALTH-2013-2.4.1-2 under grant agreement #602239<br>Co-ordinator Martin Pule, University College London, WC1E 6HX, UK</td></tr></table><br></body></html>